{"name":"Disc Medicine","slug":"disc-medicine","ticker":"IRON","exchange":"NASDAQ","domain":"discmedicine.com","description":"Disc Medicine is a rare hematology biotech company focused on developing innovative treatments for patients with rare blood disorders. The company's pipeline includes several promising candidates, including its lead asset, DSC-TRO196. With a strong focus on rare hematology, Disc Medicine is well-positioned to capitalize on the growing demand for targeted therapies in this space.","hq":"Waltham, MA","founded":0,"employees":"","ceo":"John Quisel","sector":"Rare Hematology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$2.8B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":170640000,"netIncome":-212184000,"cash":91145000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"DSC-TRO196 patent cliff ($0.0B at risk)","drug":"DSC-TRO196","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"DISC-0974","genericName":"DISC-0974","slug":"disc-0974","indication":"Other","status":"phase_2"},{"name":"DISC-3405","genericName":"DISC-3405","slug":"disc-3405","indication":"Other","status":"phase_2"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DISC-1459","genericName":"DISC-1459","slug":"disc-1459","indication":"Hereditary hemochromatosis","status":"phase_3"}]}],"pipeline":[{"name":"DISC-1459","genericName":"DISC-1459","slug":"disc-1459","phase":"phase_3","mechanism":"DISC-1459 is a hepcidin mimetic that increases hepcidin levels to reduce iron absorption and circulating iron, thereby treating iron overload disorders.","indications":["Hereditary hemochromatosis","Transfusion-dependent anemias with iron overload"],"catalyst":""},{"name":"DISC-0974","genericName":"DISC-0974","slug":"disc-0974","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DISC-3405","genericName":"DISC-3405","slug":"disc-3405","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Disc Medicine Announces FDA Fast Track Designation for DSC-TRO196","summary":"Disc Medicine announced that the FDA has granted Fast Track designation to DSC-TRO196 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).","drugName":"DSC-TRO196","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Disc Medicine Reports Third Quarter 2023 Financial Results","summary":"Disc Medicine reported its third quarter 2023 financial results, with a net loss of $24.4 million and a cash balance of $343.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Disc Medicine Announces Collaboration with University of Pennsylvania","summary":"Disc Medicine announced a collaboration with the University of Pennsylvania to develop novel treatments for rare blood disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"regulatory","source":"simplywall.st","summary":"Disc Medicine (IRON) Is Up 7.2% After Advancing Bitopertin Phase 3 Despite FDA Efficacy Concerns - simplywall.st","headline":"Disc Medicine (IRON) Is Up 7.2% After Advancing Bitopertin Phase 3 Despite FDA Efficacy Concerns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQa0w3dFF2VHBVVFhjcm1jRWFQZXgtZFRVVlhtOTRjd2ZvVUZnTVpyM2lZS01SNE1VV3J0NnUtN2FRdE1maUhBbmc2RkQ0S3dGakxvTDU5eDhNUzYzYkJSRGRRc2xxSkthQTR6aU5IV25lT1lySF9OeXFxdThnUGxqYlBtdVctbFJMX3Z0QS11RkQtbWNtcGpnQndZMXU3RWhiMENYQWZFb2hPa094YnhrMg?oc=5","date":"2026-03-30","type":"deal","source":"BNN Bloomberg","summary":"Hot Picks: Pharma stocks gain on pipelines and deals - BNN Bloomberg","headline":"Hot Picks: Pharma stocks gain on pipelines and deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQWU9uWGhsYXJkYmt0TFBpOUdpam42MEtld0p0dmxJR1VJZmFyZHNtcXRsYmE5S3BoaHlrZFl0MTh5MWNPblJ5RjdWQ3h2dU1MRXdSLUxsUlBXb3FfdEt4UUIwMmJ4R1pCb2kwOHFNZmZfdjlPcFB5MVJGcVh2RUZ2c1VxRVNYWTU5RFo2NE1DejhPSXpDMVFnN0thMWZ3TGpvUXlWdGZRU2QzSjZTR2ZkbERCempCb2M?oc=5","date":"2026-03-25","type":"regulatory","source":"Fierce Pharma","summary":"FDA approves Denali's Hunter syndrome drug, handing rare disease community a win - Fierce Pharma","headline":"FDA approves Denali's Hunter syndrome drug, handing rare disease community a win","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxOdmNPNC0ybXlkVFlsdU0ySnVvN2NPTEJYZzliR0FkRnpMWjNpU1Y5UHZ2aUdzNEFfcHRKMGQ2LS1idU5zWHdZWUU4eG1hbDZVRFdPMWtnbjc1dkt6SWhCSHNlaFVZREpYdU9EZEp0U29VTnpReDd3c2RYM0Z2SmoxX0xQVmJOTWNyUXlHZkQ4djZDZTdEWTNfenB0OHJrZnRuMXR1SzBJLTZURGhqQUthZmZJR2xNaFFUNXpfWHZKckVtekJzXzZsbklabTNCVS1wNVhwcV9rSGFfUFptcXJnemF5ZFR2YVVGd3BBN1JIN3dncmpCR0FuOXlPaWMzUnJPQ1JKSw?oc=5","date":"2026-03-18","type":"pipeline","source":"GlobeNewswire","summary":"IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire","headline":"IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOamQ2aERSNmNncDB0U1RnZDBfVHZzUFJXVVpISGs5MHZrMTZyOWRIYTZfUWtIYldsYW45RURxaFB6VWE0emY5dXdfTzc5TUJISzRKTmJNNS12dGFreUtFSS0tczBwOHpheU45bWtsU21ndW41bUkxOE5keG9vQjJ1cmdGX0hZZGF1a1VFMHR0ZHlRMUFBbTRnMmJreUZXc2JrRXRxSkEwZ2dFX0psUW1WTENFSXpCRTlNWFJ4VWVMQm1OOEJjanVpSmNTelhicW9wMzhtUXJ5ak9YdS05S2pDUVlRakJvT3h0V3d4ZHJaU0hDMXVibk8yUGczd255Sjkwd29WQ2ZYcVAxOTR6OWhsMXNDS1VWaHdCU0tpc1M3MDlpcXM2MG1kZkQwZjg3eU81QXlFN1hkOE9KbHByVWpib3lsSm0?oc=5","date":"2026-03-03","type":"regulatory","source":"PR Newswire","summary":"Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight - PR Newswire","headline":"Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diag","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQY0QxeE43SFZJdHAwQ292UkFEekJTbEYxOERxdHc5ZXJQNkpxNFU0M3lmZHNJTWdvcWZ3Z3lyOTl5cU5BTmR6UVNLRjdhU0twYWROdHBkVHctT2EwZnB2X1lBUS00SEtvUUxPV1NETk9YUWJRczVHSkxNMVB2VGpvWWNjbHEtM05XUV92NDlnNjk4bEtYMXl2S3AwRUgtc2hpUEt0MWNPTDJvNDc5S2ZqN0dGcjcyeTRudFVSMFd1cF9QdDFBbnNRc0tzamwzS2ZsMUZoS203WHNSUFA2QmV3M2cxQQ?oc=5","date":"2026-02-17","type":"regulatory","source":"reuters.com","summary":"Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod - reuters.com","headline":"Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQUVuZDVOTzhmSEMtUU41dzY0Sl9ZcnhITWFweDhxZEoycWVmZVlHcGltbW14cEF5YkhyNjdOM3hES2NMWTFvLVUxUkpjRk5udEpJcUE5dXVNS3A2S2J4WkZVVTg1VHlVWUlhNFlQcnotUFNXdjh5QWJac0hIMnRkdWwxSjFHLV8xenFrS0hNS1IzbXpheXBsa1ItQlF3Y19tYmJ3b2o0ZVV0UE5kRlZteS1kemZ0Ujh3QmdR?oc=5","date":"2026-02-16","type":"regulatory","source":"MedCity News","summary":"Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA - MedCity News","headline":"Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxORmVicTJreUQ5ZXFjbjktY1E1enJGTzQ2UDhpSVE5NVJQS1kybDNrQUo5M3J4cFdIU21uZ3hDcGhTaE93WWp0MFRVY2JUSjVlRHVJUUhRb0VNdER0Y1duQWk0RE0xNVdTQ1l0bzBSWDAxZDlJYlZHcXRVTXFYR3pIWXBRblU2N2ZFc2pMcmhXS0s0bmpKVHc?oc=5","date":"2026-02-14","type":"regulatory","source":"The Pharma Letter","summary":"FDA slaps CRL on Disc Medicine’s bitopertin NDA - The Pharma Letter","headline":"FDA slaps CRL on Disc Medicine’s bitopertin NDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOWF2dURDQnBQNmtoanYxWS1WLURYbC10cDU5YXdyQktPX2xvUm1uamQxak5kRFByVkJHcjlJLVkxNmEzMFFpQ0hBTWs1amEyU1ctOXRTeF9VOEdhNlctc1Rob1FTT3o0OWM0QnZGQmU5QzJtV2dRUGtrNjFiRkd3T1U0NHhGbDdObjZLX1VTMEs0dV90RlF2M3dsT3VIMlp3LS1WOWc0Yzlhcm82SWEzQ3NTbHNFMjRlQ25heV94NTZIV2FNSVowZzE5aXdSakxj?oc=5","date":"2025-12-19","type":"regulatory","source":"Stocktwits","summary":"Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’ - Stocktwits","headline":"Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNckdFN05HbXNVX01FTVpPZFQ4aHZyRGhqSWg1VWtzbnJzX2ZHUGo3bV9DRmpoWFB3dFF5RlpVRW9WOHJwdVZWN0lhWEt5c0prMGE2SjJlXzk5X1lIdFVGMW9vQk95cEN0UFlPWVNveS11V2VLMEZCZXRiak1UMFJGMHJJOF9yVzNfSzRnTHNXQkQ4NGZobEdLRnFMV3VtcVJ6TVpxMFVISWw?oc=5","date":"2025-11-24","type":"pipeline","source":"C&EN","summary":"How Disc Medicine rescued a discarded drug candidate - C&EN","headline":"How Disc Medicine rescued a discarded drug candidate - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE40eExtb29oZHZMNHROWnRQUkthSDVBMUU2cXlZOHF2SXpnZHpxbUhfemFsYWVSZmJwOFIwOUZMQjdfTzlVeEdPbTVBaXhjdGVWaFAxLTg2WmlrMFZndlZxVHl5NnVpRkU3bzdsRGxyaGllZFF0cGpFN1Nfcw?oc=5","date":"2025-10-18","type":"regulatory","source":"Yahoo Finance","summary":"Why Disc Medicine (IRON) Is Up 28.7% After Securing FDA Priority Review for Bitopertin Accelerated Approval - Yahoo Finance","headline":"Why Disc Medicine (IRON) Is Up 28.7% After Securing FDA Priority Review for Bitopertin Accelerated Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPRXVZemFFSEdOSVdrcmRoSmUyczZiZFBsd0lRLUxoY2pwdWZ6WUZobzJvY01hUGE0SE1rZlJvcEY2R2EyTE1SU0lBQXdUZ3BHZnV3TTBjWkhIUk1IYmZfXzlWY1pnc1NRVWh2d05zckdYLXRGcW5iWmJQanBmQ2JYdlgyQUREOUF3eGp6UUVaTXcyMVNSdm9mSUVsNnd5UQ?oc=5","date":"2025-10-17","type":"regulatory","source":"Investor's Business Daily","summary":"The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. - Investor's Business Daily","headline":"The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. - Investor's Business Daily","sentiment":"neutral"}],"patents":[{"drugName":"DSC-TRO196","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_3":1,"phase_2":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["bluebird bio","CRISPR Therapeutics","Editas Medicine"],"therapeuticFocus":["Rare Hematology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":170640000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-212184000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":91145000,"cashHistory":[],"totalAssets":806879000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}